patiromer calcium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5056 1415477-49-4

Description:

MoleculeDescription

Synonyms:

  • patiromer calcium
  • patiromer sorbitex calcium
  • veltassa
  • RLY5016S
  • patiromer
  • RLY5016
  • patiromer glucitol calcium
binds potassium ions in the gastrointestinal tract to lower serum potassium levels
  • Molecular weight:
  • Formula: (C34H52CaO16(C2H3)n(C2H2F)m(C2H3)n(C2H3)p(C2H3)p)x
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
8.40 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 19, 2017 EMA VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
Oct. 21, 2015 FDA RELYPSA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 630.92 40.70 364 4109 374017 63110532
Hospitalisation 404.31 40.70 169 4304 84912 63399637
Blood potassium increased 268.86 40.70 84 4389 18225 63466324
Constipation 230.49 40.70 161 4312 224782 63259767
Product dose omission issue 190.65 40.70 146 4327 234167 63250382
Loss of employment 170.64 40.70 38 4435 2206 63482343
Product colour issue 132.41 40.70 25 4448 632 63483917
Off label use 117.53 40.70 186 4287 674276 62810273
No adverse event 103.88 40.70 53 4420 41352 63443197
Dialysis 101.10 40.70 35 4438 10392 63474157
Product taste abnormal 98.72 40.70 24 4449 2043 63482506
Hepatic steatosis 96.74 40.70 45 4428 28724 63455825
Diarrhoea 92.48 40.70 173 4300 715193 62769356
Gastric disorder 91.31 40.70 47 4426 37322 63447227
Cardiac failure congestive 86.85 40.70 63 4410 92370 63392179
Inappropriate schedule of product administration 82.42 40.70 64 4409 103901 63380648
Abdominal pain upper 69.70 40.70 79 4394 206365 63278184
Abdominal discomfort 66.04 40.70 96 4377 320789 63163760
Product solubility abnormal 57.02 40.70 13 4460 837 63483712
Flatulence 55.43 40.70 33 4440 34669 63449880
Malaise 53.86 40.70 101 4372 415853 63068696
Product physical issue 45.50 40.70 16 4457 4964 63479585
Nausea 41.70 40.70 143 4330 854328 62630221

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 927.71 40.84 574 3681 397475 34555201
Hospitalisation 539.19 40.84 216 4039 56686 34895990
Constipation 406.45 40.84 234 4021 136748 34815928
Product dose omission issue 287.79 40.84 179 4076 119532 34833144
Blood potassium increased 262.84 40.84 92 4163 16403 34936273
Dialysis 184.12 40.84 64 4191 11144 34941532
Product taste abnormal 114.75 40.84 27 4228 1147 34951529
Off label use 90.94 40.84 173 4082 419351 34533325
Inappropriate schedule of product administration 89.18 40.84 68 4187 62228 34890448
Product colour issue 87.82 40.84 19 4236 549 34952127
Flatulence 83.58 40.84 44 4211 21154 34931522
No adverse event 72.14 40.84 41 4214 22886 34929790
Diarrhoea 68.99 40.84 148 4107 389764 34562912
Abdominal discomfort 61.73 40.84 54 4201 59781 34892895
Product solubility abnormal 61.70 40.84 14 4241 505 34952171
Product physical issue 59.59 40.84 19 4236 2522 34950154
Treatment noncompliance 49.93 40.84 35 4220 28065 34924611
Abdominal pain upper 41.15 40.84 47 4208 71443 34881233

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1014.77 40.62 603 5925 565911 79171949
Hospitalisation 478.12 40.62 205 6323 94031 79643829
Constipation 396.16 40.62 260 6268 282790 79455070
Product dose omission issue 367.26 40.62 236 6292 247301 79490559
Blood potassium increased 325.77 40.62 113 6415 29162 79708698
Off label use 174.65 40.62 284 6244 906931 78830929
Loss of employment 159.53 40.62 38 6490 2549 79735311
Abdominal discomfort 127.71 40.62 128 6400 250599 79487261
Dialysis 123.15 40.62 49 6479 18413 79719447
Diarrhoea 120.52 40.62 238 6290 880251 78857609
Product taste abnormal 112.66 40.62 28 6500 2243 79735617
Flatulence 108.61 40.62 58 6470 42666 79695194
Inappropriate schedule of product administration 106.88 40.62 88 6440 133540 79604320
Gastric disorder 101.33 40.62 53 6475 37380 79700480
Abdominal pain upper 98.98 40.62 106 6422 223713 79514147
Cardiac failure congestive 82.26 40.62 78 6450 142324 79595536
Product colour issue 81.47 40.62 18 6510 862 79736998
Product solubility abnormal 79.69 40.62 18 6510 954 79736906
Hepatic steatosis 78.77 40.62 45 6483 37693 79700167
Product physical issue 61.71 40.62 20 6508 4165 79733695
No adverse event 53.59 40.62 35 6493 37157 79700703
Malaise 53.24 40.62 121 6407 489748 79248112
Treatment noncompliance 40.82 40.62 34 6494 52234 79685626

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AE09 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Drugs for treatment of hyperkalemia and hyperphosphatemia
FDA MoA N0000178377 Potassium Ion Binding Activity
FDA EPC N0000178378 Potassium Binder

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperkalemia indication 14140009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 10485821 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8287847 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8475780 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8778324 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8889115 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 10485821 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8287847 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8475780 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8778324 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8889115 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 10485821 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8287847 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8475780 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8778324 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8889115 March 30, 2024 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 7556799 Feb. 27, 2025 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 7556799 Feb. 27, 2025 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 7556799 Feb. 27, 2025 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8216560 March 14, 2027 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8216560 March 14, 2027 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8216560 March 14, 2027 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8337824 May 29, 2030 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8337824 May 29, 2030 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 8337824 May 29, 2030 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 11123363 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 9492476 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 9925212 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 11123363 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 9492476 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 9925212 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 11123363 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 9492476 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET VELTASSA VIFOR PHARMA N205739 Oct. 21, 2015 RX POWDER ORAL 9925212 Oct. 8, 2033 TREATMENT OF HYPERKALEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
7T97I3787N UNII
D10149 KEGG_DRUG
1260643-52-4 SECONDARY_CAS_RN
4035186 VANDF
C4301626 UMLSCUI
CHEMBL2107840 ChEMBL_ID
CHEMBL2107875 ChEMBL_ID
9532 INN_ID
C568789 MESH_SUPPLEMENTAL_RECORD_UI
DB09263 DRUGBANK_ID
1716203 RXNORM
236636 MMSL
31246 MMSL
d08388 MMSL
016559 NDDF
016560 NDDF
715260008 SNOMEDCT_US
763550001 SNOMEDCT_US
1208912-84-8 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VELTASSA HUMAN PRESCRIPTION DRUG LABEL 1 53436-084 POWDER, FOR SUSPENSION 8.40 g ORAL NDA 26 sections
VELTASSA HUMAN PRESCRIPTION DRUG LABEL 1 53436-084 POWDER, FOR SUSPENSION 8.40 g ORAL NDA 26 sections
VELTASSA HUMAN PRESCRIPTION DRUG LABEL 1 53436-168 POWDER, FOR SUSPENSION 16.80 g ORAL NDA 26 sections
VELTASSA HUMAN PRESCRIPTION DRUG LABEL 1 53436-168 POWDER, FOR SUSPENSION 16.80 g ORAL NDA 26 sections
VELTASSA HUMAN PRESCRIPTION DRUG LABEL 1 53436-252 POWDER, FOR SUSPENSION 25.20 g ORAL NDA 26 sections
VELTASSA HUMAN PRESCRIPTION DRUG LABEL 1 53436-252 POWDER, FOR SUSPENSION 25.20 g ORAL NDA 26 sections